REGN Regeneron Pharmaceuticals Inc.

401.21
-3.54  -1%
Previous Close 404.75
Open 404.92
Price To Book 5.52
Market Cap 43424789422
Shares 108,234,564
Volume 907,773
Short Ratio
Av. Daily Volume 766,112

SEC filingsSee all SEC filings

  1. 8-K - Current report 19512159
  2. 8-K - Current report 181238224
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181178431
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161532
  5. 8-K - Current report 181161503

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
FDA Approval announced August 17, 2018.
EYLEA
Wet AMD
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial enrolling.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
PDUFA date under priority review March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
PDUFA date for sBLA filing April 28, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
REGN2810
Non-small cell lung cancer (NSCLC)
Data due 2020.
Cemiplimab
Basal cell carcinoma
Phase 2 enrolling as of September 2017. BLA filing due 1Q 2018 pending data.
REGN2810
Basal cell carcinoma
Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
REGN2222
Respiratory syncytial virus (RSV)
PDUFA date for sBLA May 13, 2019.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 data released October 16, 2018 - primary and secondary endpoints met. sBLA filing 1Q 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Fasinumab
Osteoarthritis and chronic low back pain
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 2 data released May 4, 2017. Phase 3 trial to be initiated 1Q 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 2 trial to commence 1H 2019.
REGN1979
Follicular Lymphoma

Latest News

  1. Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
  2. 5 Best Biotech Bets Likely to Outperform Estimates in Q4
  3. Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
  4. See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
  5. 3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?
  6. These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
  7. Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
  8. Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
  9. J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
  10. Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell — New Horizons, Emerging Trends, and Upcoming Developments
  11. Regeneron (REGN) Sails Steady on Label Expansion of Drugs
  12. REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds
  13. 3 of the Top Big Pharma Stocks to Buy Now
  14. Can Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Maintain Its Strong Returns?
  15. How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
  16. 5 Companies Hit 52-Week Highs
  17. Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
  18. 3 Biotech Stocks Bubbling Away

SEC Filings

  1. 8-K - Current report 19512159
  2. 8-K - Current report 181238224
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181178431
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161532
  5. 8-K - Current report 181161503
  6. 8-K - Current report 181119299
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988404
  8. 8-K - Current report 18986687
  9. CT ORDER - Confidential treatment order 18971314
  10. 8-K - Current report 18896716